Top Markets
#1 Islamic Coin Islamic Coin +151.51%
#2 Akedo Akedo +69.87%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.42%
#5 Velvet Velvet +46.01%
#6 Cross Cross +36.90%
#7 Black Phoenix Black Phoenix +34.13%
#8 Cap Cap +19.51%
#9 DoubleZero DoubleZero +15.07%
#10 Humanity Humanity +11.75%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Exopharm Limited Exopharm Limited

Exopharm Limited

EX1
Rank in Stocks #39131
Exopharm Limited is an Australian clinical-stage firm dedicated to developing... Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.
Share Price
$0.00700343
Last synced: 2023-10-30
Market Cap
$637.31K
Change (1 day)
0.50%
Change (1 year)
0.00%
Country
AU
Trade Exopharm Limited (EX1)

Category

Healthcare
Revenue for Exopharm Limited (EX1)
Revenue in Aug 2026 TTM: 0
According to Exopharm Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Exopharm Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE